Hadasit Bio-Holdings Ltd (HSITF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.77 Million ILS | 34.79% |
| 2022 | -2.72 Million ILS | 59.59% |
| 2021 | -2.07 Million ILS | -156.21% |
| 2020 | 11.41 Million ILS | 152.5% |
| 2019 | -3.26 Million ILS | -226.29% |
| 2018 | -3.86 Million ILS | 34.51% |
| 2017 | -2.1 Million ILS | 35.44% |
| 2016 | -2.68 Million ILS | -7.1% |
| 2015 | -16.35 Million ILS | -19.43% |
| 2014 | -12.32 Million ILS | 25.14% |
| 2013 | -12.63 Million ILS | 0.5% |
| 2012 | -16.54 Million ILS | 23.47% |
| 2011 | -21.61 Million ILS | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -435.5 Thousand ILS | -78.36% |
| 2023 Q4 | -239.88 Thousand USD | 44.92% |
| 2023 FY | - ILS | 34.79% |
| 2023 Q1 | -453.5 Thousand ILS | -15.73% |
| 2023 Q2 | -244.17 Thousand USD | 46.16% |
| 2022 Q2 | -675 Thousand USD | 0.0% |
| 2022 Q1 | -675 Thousand ILS | -22.5% |
| 2022 FY | - ILS | 59.59% |
| 2022 Q4 | -391.87 Thousand USD | 43.17% |
| 2022 Q3 | -689.5 Thousand ILS | -2.15% |
| 2021 FY | - ILS | -156.21% |
| 2021 Q4 | -551 Thousand ILS | 0.0% |
| 2021 Q3 | -551 Thousand ILS | -12.79% |
| 2021 Q1 | -488.5 Thousand ILS | 14.37% |
| 2021 Q2 | -488.5 Thousand ILS | 0.0% |
| 2020 Q3 | -570.5 Thousand ILS | 0.95% |
| 2020 FY | - ILS | 152.5% |
| 2020 Q2 | -576 Thousand ILS | 0.0% |
| 2020 Q1 | -576 Thousand ILS | 42.46% |
| 2020 Q4 | -570.5 Thousand ILS | 0.0% |
| 2019 Q3 | -1.23 Million ILS | -140.7% |
| 2019 Q1 | -513.5 Thousand ILS | 0.0% |
| 2019 Q2 | -513.5 Thousand ILS | 0.0% |
| 2019 FY | - ILS | -226.29% |
| 2019 Q4 | -1 Million ILS | 19.01% |
| 2018 Q1 | 183 Thousand ILS | -98.53% |
| 2018 Q2 | 183 Thousand ILS | 0.0% |
| 2018 FY | - ILS | 34.51% |
| 2017 Q2 | -4.41 Million ILS | 0.0% |
| 2017 FY | - ILS | 35.44% |
| 2017 Q4 | 12.44 Million ILS | 317.32% |
| 2017 Q1 | -4.41 Million ILS | 20.39% |
| 2017 Q3 | -5.72 Million ILS | -29.85% |
| 2016 Q1 | -2.18 Million ILS | 64.68% |
| 2016 Q4 | -5.54 Million ILS | -162.68% |
| 2016 Q3 | -2.1 Million ILS | -8.82% |
| 2016 Q2 | -1.93 Million ILS | 11.34% |
| 2016 FY | - ILS | -7.1% |
| 2015 Q1 | -12.03 Million ILS | -129.16% |
| 2015 Q4 | -6.18 Million ILS | -152.92% |
| 2015 FY | - ILS | -19.43% |
| 2015 Q3 | -2.44 Million ILS | -10.13% |
| 2015 Q2 | -2.22 Million ILS | 81.53% |
| 2014 Q3 | -2.06 Million ILS | -270.57% |
| 2014 Q2 | 1.21 Million ILS | 158.88% |
| 2014 Q4 | -5.25 Million ILS | -153.79% |
| 2014 FY | - ILS | 25.14% |
| 2014 Q1 | -2.06 Million ILS | 76.9% |
| 2013 Q3 | -4.21 Million ILS | 5.37% |
| 2013 FY | - ILS | 0.5% |
| 2013 Q1 | -756 Thousand ILS | 90.54% |
| 2013 Q2 | -4.45 Million ILS | -489.02% |
| 2013 Q4 | -8.91 Million ILS | -111.65% |
| 2012 Q1 | -3.88 Million ILS | 0.0% |
| 2012 FY | - ILS | 23.47% |
| 2012 Q3 | -3.48 Million ILS | -360.69% |
| 2012 Q4 | -7.98 Million ILS | -129.04% |
| 2012 Q2 | 1.33 Million ILS | 134.48% |
| 2011 FY | - ILS | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -26.836% |
| CSL Limited | 4.78 Billion USD | 100.037% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.497% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 70.011% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -643.466% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 89.764% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.891% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -15.752% |
| Mesoblast Limited | -62.38 Million USD | 97.15% |
| Marizyme, Inc. | -34.28 Million USD | 94.814% |
| Genus plc | 73.7 Million USD | 102.412% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 73.108% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 49.873% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 79.731% |
| ContraFect Corporation | -64.99 Million USD | 97.265% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 60.718% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | 94.995% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 23.488% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -243.213% |
| Accustem Sciences Inc. | -3.74 Million USD | 52.541% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.313% |
| EV Biologics, Inc. | -1.26 Million USD | -40.317% |
| Q BioMed Inc. | -617.62 Thousand USD | -187.876% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 149.776% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 22.171% |
| Biomind Labs Inc. | -1.03 Million USD | -71.862% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 75.172% |
| Skye Bioscience, Inc. | -13.54 Million USD | 86.876% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.228% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -7012.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 54.226% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 32.765% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 88.796% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -181.149% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 118.001% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -19.536% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 28.936% |
| GB Sciences, Inc. | -1.41 Million USD | -25.221% |
| Alpha Cognition Inc. | -9.7 Million USD | 81.681% |
| argenx SE | -216.02 Million USD | 99.177% |
| HST Global, Inc. | -5303.00 USD | -33428.192% |
| Halberd Corporation | -74.27 Thousand USD | -2293.678% |
| Enzolytics Inc. | -2.12 Million USD | 16.212% |
| Resverlogix Corp. | -11.74 Million USD | 84.858% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 41.953% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 96.787% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 95.514% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 246.097% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 38.527% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 120.082% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 26542.594% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -18.62% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 569.322% |
| AVAX Technologies, Inc. | -6.11 Million USD | 70.913% |
| ONE Bio Corp. | 13.61 Million USD | 113.061% |
| Zenith Capital Corp. | -8.6 Million USD | 79.34% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.285% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -10106.073% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 27.324% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -910.087% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 7.44% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 13.563% |
| Agentix Corp. | -1.37 Million USD | -29.615% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | 32.251% |
| Helix BioMedix, Inc. | -1.04 Million USD | -69.93% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1.6% |
| BioStem Technologies, Inc. | -7.55 Million USD | 76.462% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -881.843% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 531.257% |
| Cell Source, Inc. | -4.27 Million USD | 58.385% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -384.177% |
| Regen BioPharma, Inc. | 1.46 Million USD | 221.286% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -89.765% |
| NovAccess Global Inc. | -1.03 Million USD | -71.821% |
| Affymax, Inc. | -14.29 Million USD | 87.562% |
| Itoco Inc. | -1.86 Million USD | 4.869% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -368.363% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -59.319% |
| CytoDyn Inc. | -18.02 Million USD | 90.138% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2149.807% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -14439.21% |
| Qrons Inc. | -40.08 Thousand USD | -4336.017% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -266.086% |
| SYBLEU INC | -141.57 Thousand USD | -1155.907% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 437.104% |
| Rebus Holdings, Inc. | -951 Thousand USD | -86.961% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -67.418% |
| Mobile Lads Corp. | -2.24 Million USD | 20.666% |
| International Stem Cell Corporation | 202 Thousand USD | 980.198% |
| Bioxytran, Inc. | -3.82 Million USD | 53.457% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3277.66% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 27.78% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.043% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3851.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 35.062% |
| Neutra Corp. | -181.24 Thousand USD | -880.982% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 91.18% |
| PureTech Health plc | -11.62 Million USD | 84.708% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 91.18% |
| IXICO plc | -707 Thousand USD | -151.485% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 76.864% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.322% |
| CSL Limited | 4.73 Billion USD | 100.038% |
| Cellectis S.A. | -92.63 Million USD | 98.081% |